Palvella completes FDA submission for first-ever treatment for microcystic lymphatic malformations

Palvella Therapeutics has finished submitting its application to the US Food and Drug Administration (FDA) for QTORIN rapamycin, a topical gel that would become the first approved treatment for microcystic lymphatic malformations — a rare, lifelong genetic condition in which malformed lymphatic vessels cause painful, leaking, infection-prone lesions in the skin and soft tissue. There is currently no approved therapy, and Palvella estimates more than 30,000 children and adults in the US live with the disease.

The company used the FDA's "rolling review" process, which lets a developer send in sections of its application as they are ready rather than waiting to file everything at once — a mechanism reserved for promising treatments for serious conditions. The FDA had already granted QTORIN rapamycin its Breakthrough Therapy, Fast Track and Orphan Drug designations, all of which are meant to speed development of drugs for serious or rare diseases.

The submission is backed by Palvella's Phase 3 SELVA trial, the final stage of human testing. The study hit its main goal and every one of its six efficacy measures with statistically significant results (meaning the benefit was very unlikely to be down to chance). The FDA now has 60 days to decide whether to accept the application for review and whether to grant Priority Review, which would shorten its assessment to roughly six months. Palvella is preparing for a potential commercial launch in the first half of 2027 if the drug is approved.

Source: Palvella Therapeutics (GlobeNewswire), 31 August 2026.